CUMBERLAND PHARMACEUTICALS INC Quarterly Revenues in USD from Q1 2017 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Cumberland Pharmaceuticals Inc quarterly/annual Revenues history and growth rate from Q1 2017 to Q4 2022.
  • Cumberland Pharmaceuticals Inc Revenues for the quarter ending December 31, 2022 was $9.12M, a 9.66% increase year-over-year.
  • Cumberland Pharmaceuticals Inc Revenues for the twelve months ending December 31, 2022 was $42M, a 16.7% increase year-over-year.
  • Cumberland Pharmaceuticals Inc annual Revenues for 2022 was $42M, a 16.7% increase from 2021.
  • Cumberland Pharmaceuticals Inc annual Revenues for 2021 was $36M, a 3.89% decline from 2020.
  • Cumberland Pharmaceuticals Inc annual Revenues for 2020 was $37.4M, a 8.88% increase from 2019.
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $42M $9.12M +$804K +9.66% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-13
Q3 2022 $41.2M $11.4M +$3.34M +41.4% Jul 1, 2022 Sep 30, 2022 10-K 2023-03-13
Q2 2022 $37.9M $10.3M +$1.24M +13.7% Apr 1, 2022 Jun 30, 2022 10-K 2023-03-13
Q1 2022 $36.6M $11.2M +$638K +6.05% Jan 1, 2022 Mar 31, 2022 10-K 2023-03-13
Q4 2021 $36M $8.32M -$1.94M -18.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-13
Q3 2021 $37.9M $8.07M -$1.18M -12.7% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-13
Q2 2021 $39.1M $9.06M -$543K -5.65% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-13
Q1 2021 $39.6M $10.5M +$2.21M +26.5% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-13
Q4 2020 $37.4M $10.3M +$956K +10.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 $36.5M $9.25M +$2.32M +33.4% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-11
Q2 2020 $34.2M $9.6M +$181K +1.92% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-11
Q1 2020 $34M $8.33M -$399K -4.57% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-11
Q4 2019 $34.4M $9.31M -$1.18M -11.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 $35.6M $6.94M +$1.08M +18.5% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-12
Q2 2019 $34.5M $9.42M +$2.33M +32.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-12
Q1 2019 $32.2M $8.73M +$2.81M +47.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-12
Q4 2018 $29.3M $10.5M -$1.16M -9.97% Oct 1, 2018 Dec 31, 2018 8-K 2020-12-10
Q3 2018 $30.5M $5.85M -$5.34M -47.7% Jul 1, 2018 Sep 30, 2018 8-K 2020-12-10
Q2 2018 $35.8M $7.08M -$1.58M -18.3% Apr 1, 2018 Jun 30, 2018 8-K 2020-12-10
Q1 2018 $37.4M $5.92M -$3.72M -38.6% Jan 1, 2018 Mar 31, 2018 8-K 2020-12-10
Q4 2017 $41.2M $11.6M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 $11.2M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 $8.67M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 $9.64M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.